Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13176827 | 1.00 | TDP1 (0.42) | TDP1TSHRLMNAL3MBTL1ALDH1A1 | |
| SCHEMBL13471599 | 1.00 | TDP1 (0.42) | TDP1TSHRLMNAL3MBTL1ALDH1A1 | |
| SCHEMBL10027479 | 1.00 | TDP1 (0.42) | TDP1TSHRLMNAL3MBTL1ALDH1A1 | |
| SCHEMBL19820226 | 1.00 | TDP1 (0.42) | TDP1TSHRLMNAL3MBTL1ALDH1A1 | |
| SCHEMBL18271003 | 0.91 | TDP1 (0.50) | TDP1TSHRLMNAL3MBTL1ALDH1A1 | |
| SCHEMBL15889663 | 0.91 | TDP1 (0.50) | TDP1TSHRLMNAL3MBTL1ALDH1A1 | |
| SCHEMBL16074667 | 0.88 | — | — | |
| SCHEMBL14346962 | 0.87 | TDP1 (0.53) | TDP1TSHRLMNAL3MBTL1ALDH1A1 | |
| SCHEMBL23808063 | 0.82 | TDP1 (0.42) | TDP1TSHRLMNAL3MBTL1ALDH1A1 | |
| SCHEMBL2631898 | 0.82 | TDP1 (0.42) | TDP1TSHRLMNAL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2414372-B1 | CHEMICAL SYNTHESIS OF PHOSPHATIDYLINOSITOL MANNOSIDE GLYCANS FROM MYCOBACTERIUM TUBERCULOSIS | MAX PLANCK GESELLSCHAFT (DE) | 2013-10-23 | — | — | EP | disclosed |
| EP-1689789-B1 | NOVEL CYCLODEXTRIN DIMERS AND DERIVATIVES THEREOF, METHODS FOR PREPARING THEM AND THEIR USE, IN PARTICULAR, FOR SOLUBILIZING PHARMACOLOGICALLY ACTIVE SUBSTANCES | CENTRE NAT RECH SCIENT (FR) | 2009-11-11 | — | — | EP | disclosed |
| US-20090069448-A1 | Degradable polymer and process for production thereof | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069448-A1 | Degradable polymer and process for production thereof | HPGDS, PPOX, HCCS | TDP1 849/4885TSHR 4225/4885LMNA 3436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.